Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:CRON OTCMKTS:STDAF NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$0.97+2.5%$1.08$0.84▼$2.38$381.37M0.777.30 million shs2.64 million shsCRONCronos Group$2.71+1.5%$2.69$1.84▼$3.43$996M0.891.13 million shs1.22 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/ATLRYTilray Brands$4.73-0.4%$5.81$3.51▼$23.20$553.61M1.883.41 million shs3.55 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth+2.49%-4.24%-2.01%+2.37%-25.02%CRONCronos Group+1.50%-1.63%+3.83%+13.39%+41.88%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands-0.42%-7.62%-9.21%-23.83%+23.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$0.97+2.5%$1.08$0.84▼$2.38$381.37M0.777.30 million shs2.64 million shsCRONCronos Group$2.71+1.5%$2.69$1.84▼$3.43$996M0.891.13 million shs1.22 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/ATLRYTilray Brands$4.73-0.4%$5.81$3.51▼$23.20$553.61M1.883.41 million shs3.55 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth+2.49%-4.24%-2.01%+2.37%-25.02%CRONCronos Group+1.50%-1.63%+3.83%+13.39%+41.88%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands-0.42%-7.62%-9.21%-23.83%+23.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 2.17HoldN/AN/ACRONCronos Group 2.20Hold$2.30-15.13% DownsideSTDAFSTADA Arzneimittel Aktiengesellschaft 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$11.50143.13% UpsideCurrent Analyst Ratings BreakdownLatest CGC, STDAF, CRON, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/18/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/4/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026TLRYTilray Brands ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$9.50 ➝ $9.004/2/2026TLRYTilray Brands Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$251.01M1.56N/AN/A$1.90 per share0.51CRONCronos Group$146.59M6.90$0.01 per share212.97$3.00 per share0.90STDAFSTADA Arzneimittel Aktiengesellschaft$3.84B1.79$11.12 per share9.93$23.11 per share4.78TLRYTilray Brands$821.31M0.67$1.44 per share3.29$14.04 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$0.59N/AN/AN/A-75.27%-26.95%-17.20%8/7/2026 (Estimated)CRONCronos Group-$9.45M$0.01271.27N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)STDAFSTADA Arzneimittel Aktiengesellschaft$292.15MN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest CGC, STDAF, CRON, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q4 2026CGCCanopy Growth-$0.06-$0.17-$0.11$999.00$53.43 million$51.22 million5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.313.344.26CRONCronos GroupN/A21.8720.73STDAFSTADA Arzneimittel Aktiengesellschaft2.231.540.99TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%CRONCronos Group8.71%STDAFSTADA Arzneimittel AktiengesellschaftN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%CRONCronos Group7.80%STDAFSTADA Arzneimittel AktiengesellschaftN/ATLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150404.12 million403.48 millionOptionableCRONCronos Group450373.03 million343.94 millionOptionableSTDAFSTADA Arzneimittel Aktiengesellschaft12,50062.34 millionN/ANot OptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableCGC, STDAF, CRON, and TLRY HeadlinesRecent News About These CompaniesTop Cannabis Stocks To Keep An Eye On - June 18th41 minutes ago | americanbankingnews.comTilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from Analysts2 hours ago | americanbankingnews.comTilray Brands, Inc. (NASDAQ:TLRY) Given Average Rating of "Hold" by Brokerages3 hours ago | marketbeat.comTilray Brands, Inc.: BrewDog Turns Up Father's Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 18 at 10:10 PM | finanznachrichten.deTilray Brands, Inc.: Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 10:10 PM | finanznachrichten.deHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 12:09 PM | finance.yahoo.comBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 12:09 PM | finance.yahoo.comTilray takes Hi*Ball energy brand to UKJune 18 at 12:09 PM | just-drinks.comJBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:50 AM | financialpost.comFBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:30 AM | globenewswire.comHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 7:00 AM | globenewswire.comPromising Cannabis Stocks To Follow Now - June 17thJune 18 at 4:05 AM | americanbankingnews.comAltshuler Shaham Ltd Has $857,000 Stock Holdings in Tilray Brands, Inc. $TLRYJune 18 at 3:18 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% - What's Next?June 17 at 5:47 PM | marketbeat.com3 Marijuana Stocks Investors Can See Returns On Before The End Of The YearJune 17 at 1:26 PM | marijuanastocks.comMBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 9:16 AM | finance.yahoo.comBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 7:11 AM | financialpost.comFHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:38 PM | finance.yahoo.comHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:00 PM | zacks.comTilray Brands (NASDAQ:TLRY) Shares Down 2.6% - What's Next?June 16 at 5:46 PM | marketbeat.comBreckenridge Brewery Launches a Colorado-Wide Soccer Celebration with Fan-First ActivationsJune 16 at 9:36 AM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?By Jessica Mitacek | June 1, 2026If the Market Rally Stalls, This ETF Can Insulate PortfoliosBy Jessica Mitacek | May 28, 2026CGC, STDAF, CRON, and TLRY Company DescriptionsCanopy Growth NASDAQ:CGC$0.97 +0.02 (+2.49%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.97 0.00 (-0.02%) As of 06/18/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Cronos Group NASDAQ:CRON$2.71 +0.04 (+1.50%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.69 -0.02 (-0.59%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.STADA Arzneimittel Aktiengesellschaft OTCMKTS:STDAF$110.42 0.00 (0.00%) As of 10/24/2022STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market.Tilray Brands NASDAQ:TLRY$4.73 -0.02 (-0.42%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.74 +0.00 (+0.11%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
